Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
About
About the Journal
Editorial board
The Publisher
Abstracting and indexing
Publication ethics
Privacy Statement
Contact
Policies
Open access policy
Editorial policies
Authors' self archiving and sharing policy
Commercial policies
Privacy policy
Guidelines
Guidelines for authors
Guidelines for Reviewers
Artwork guidelines
Publication fees
Archives
Current
Search
Register
Login
Submit now
Home
/
Archives
/
Vol. 4 No. 1 (2017): January-December 2017
Vol. 4 No. 1 (2017): January-December 2017
Published:
2017-12-31
Editorial (on invitation only)
Exploring the Advancing Function of Health Technology Assessments
Aileen Murphy
1-2
PDF
When Simple Becomes Complicated: Why Excel Should Lose its Place at the Top Table
Gianluca Baio, Anna Heath
3-6
PDF
Value of health technologies, HTA and decisions
Valore delle tecnologie sanitarie, HTA, decisioni
Carlo Lucioni, Claudio Jommi
41-43
PDF
Beyond cost-effectiveness, analysis. Value-based pricing and result-oriented financing as a pathway to sustainability for the national health system in Spain
Más allá Del análisis Coste-Efectividad. Precios Basados en el Valor y Financiación Orientada a Resultados Como Vía de Sostenibilidad Para el SNS en España
Alvaro Hidalgo-Vega
60-64
PDF
Review
Economic Evaluation of Family-Based Therapies for Children and Adolescents: what do we know?
Sandy Tubeuf, Sophie Guthmuller
197-207
PDF
Point of View
Cardiovascular risk and increased plasma LDL cholesterol concentration: the role of the Regional Health Service
Il rischio cardiovascolare e la concentrazione plasmatica del colesterolo LDL: il ruolo dei Servizi Sanitari Regionali
Patrizia Berto, Claudio Bilato, Enzo Bonora, Umberto De Conto, Maria Stella Graziani, Paolo Pauletto, Roberto Vettor, Alberto Zambon
44-46
PDF
The Feasibility Study: A Health Economics Perspective
Brenda Gannon
65-68
PDF
Outpatient management of oral anticoagulation treatment (OAT) in general practice: the “Medicina di Gruppo di Masate” experience
La Gestione Ambulatoriale Della Terapia Anticoagulante Orale (TAO) Nelle Cure Primarie: L'esperienza Dell'Associazione “Medicina di Gruppo di Masate”
Fiorenzo Massimo Corti, Contardo Luigi Corbetta, Maria P. Consuelo Lampreda, Giovanni Gancitano, Matteo Dionisi
84-87
PDF
Place in therapy of olmesartan
Qual è il Giusto Place in Therapy Dell'olmesartan?
Antonio Addis, Francesco Trotta
141-144
PDF
Original Research Articles
Evaluating national pricing policies of innovative anti-cancer drugs: correlation analysis between costs and survival in 15 European countries
Valutazione Della Politica di Pricing Dei Farmaci Oncologici Innovativi: Correlazione Tra Costi e Sopravvivenza in 15 Paesi Europei
Daniele Mengato, Francesca Decannas
7-10
PDF
Economic evaluation of platelet-rich-plasma versus hyaluronic acid for the treatment of knee osteoarthritis. Scenarios to 1 and 5 years
Valutazione Economica Sull'utilizzo Del Plasma Arricchito di Piastrine Vs Acido Ialuronico Per il Trattamento Dell'osteoartrosi al Ginocchio. Scenario a 1 Anno e a 5 Anni
Stefano Landi, Paolo Landa, Salvatore Russo
11-21
PDF
Cost analysis of residual viremia detected by two real-time PCR assays for response-guided (dual or triple) therapy of HCV genotype 1 infection
Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia
Alessio Aghemo, Giovanna Lunghi, Roberto Ravasio, Erminio Torresani, Matteo Dionisi, Davide Paolini, Massimo Colombo
22-27
PDF
The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland
Richéal M. Burns, Jose Leal, Jane Wolstenholme, Ciaran O’Neill, Frank J. Sullivan, Frances J. Drummond, Linda Sharp
28-33
PDF
Rapid Reviews with Health-Technology Assessments in Reimbursement Systems – an Examination of Ireland as a Case Study
Aileen Murphy, Sandra Redmond
34-40
PDF
Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidence
Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza
Marco Marchetti, Luz Irene Urbina, Marco Oradei, Matteo Ruggeri, Pierluigi Navarra
47-59
PDF
Budget impact analysis of ticagrelor for preventive treatment of patients with acute coronary syndromes
Analisi di Budget Impact di Ticagrelor nel Trattamento di Prevenzione in Pazienti con Sindrome Coronarica Acuta
Gian Piero Perna, Roberto Ravasio, Antonio Ricciardelli
69-76
PDF
The cost of Clostridium difficile infection (CDI) in hospital in Italy
Il Costo Ospedaliero di Trattamento di un Episodio di Infezione da Clostridium Difficile in Italia
Nicola Petrosillo, Roberto Ravasio
77-83
PDF
Activity-based costing and budget analysis of vedolizumab versus conventional treatments in ulcerative colitis and Crohn's disease
Analisi Organizzativa e di Budget Dell'introduzione di Vedolizumab Vs Terapie Tradizionali in Colite Ulcerosa e Morbo di Crohn
Matteo Ruggeri, Michele Basile, Alessandro Armuzzi, Americo Cicchetti
88-99
PDF
Mortality Cost of Duchenne Muscular Dystrophy
Erik Landfeldt, Michelle Eagle, Volker Straub, Hanns Lochmüller, Katharine Bushby, Peter Lindgren
100-103
PDF
Analysis of Productivity Costs in Cancer: A Systematic Review
Jordi Gol-Montserrat, María Luisa M. del Burgo, Luis Quecedo, Juan E. del Llano
104-113
PDF
Cost-Effectiveness of Azacitidine Compared with Low-Doses of Chemotherapy (LDC) in Myelodysplastic Syndrome (MDS)
Myrna Candelaria Hernández, Xavier López Karpovitch, Francisco Javier Mijangos, Efreen Montaño, Arely Lemus Carmona, Silvia Guzmán Vázquez, Herman Soto Molina
114-121
PDF
Budget impact analysis of empagliflozin in T2D patients with a previous cardiovascular disease
Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata
Sergio Iannazzo, Aldo Pietro Maggioni, Edoardo Mannucci
122-132
PDF
Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk
Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1
Christian Ramos, Efreen Montaño, Alfonso Reyes-López, Fabiola Lemus, Maria Pacheco, Gabriela Hernandez, Arely Lemus
133-140
PDF
Economic evaluation of the organizational impact of adopting different in situ hybridization technologies to assess HER2 gene amplification in breast cancer
Valutazione Economica Dell'impatto Organizzativo di Differenti Tecniche di Ibridazione in Situ per la Determinazione Dello Stato di HER2 nel Carcinoma Alla Mammella
Roberto Ravasio, Davide Paolini, Matteo Dionisi, Vincenzo Arena
145-148
PDF
Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients
Impatto Economico Dei Regimi Semplificati a Base di Raltegravir Nel Trattamento di Mantenimento Dei Pazienti HIV-1 Infetti in Soppressione Virologica
Roberto Ravasio, Mauro Maresca, Barbara Busà, Benedetto Maurizio Celesia
149-154
PDF
Including Health Economic Analysis in Pilot Studies: Lessons Learned from a Cost-Utility Analysis within the PROSPECTIV Pilot Study
Richéal M. Burns, Jane Wolstenholme, Bethany Shinkins, Emma Frith, Lauren Matheson, Peter W. Rose, Eila Watson
165-174
PDF
Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanercept
Impatto Economico Dei Biosimilari in Italia: Passato, Presente e Futuro di Infliximab ed Etanercept
Andrea Marcellusi, Luca Bianchi, Antonio Gasbarrini, Guido Valesini, Francesco Saverio Mennini
175-186
PDF
Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations
Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR
Adolfo Favaretto, Francesco Grossi, Alessandro Morabito, Roberto Ravasio
187-196
PDF
Drug utilization of biological drugs in the treatment of chronic Immune-Mediated Inflammatory Diseases (IMIDs): an observational study on Italian patients
Analisi di Farmacoutilizzazione dei Trattamenti Biologici Nelle Malattie Infiammatorie Immunomediate Croniche: I Risultati di Uno Studio Osservazionale Retrospettivo Condotto in un Centro Ospedaliero del Centro Italia
Paolo Faccendini, Enrica Cantillo, Caterina Fanizza, Maria Grazia Celeste
208-215
PDF
A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy
Sergio Iannazzo, Chiara Distante, Stefania Lopatriello, Roberto Bordonaro
221-226
PDF
Economic evaluation of therapeutic sequences in the treatment of patients with chronic lymphocytic leukemia and coexisting conditions
Una Valutazione Economica Delle Sequenze Terapeutiche nel Trattamento di Prima Linea Della Leucemia Linfatica Cronica in Pazienti Unfit non Pretrattati
Antonio Cuneo, Roberto Ravasio, Nicola Amedeo Mazzanti
227-234
PDF
The cost of antibiotic therapy and antibiotic resistance for complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs) in Italy
Il Costo Della Terapia Antibiotica e Dell'antibiotico-Resistenza Nelle Infezioni Intraddominali e Urinarie Complicate: l'esperienza di un Grande Presidio Ospedaliero Campano
Paola Saturnino, Maria Pia Mannelli, Roberto Ravasio
235-242
PDF
Current Management of Severe Refractory Asthma in Italy: Analysis of Real-World Data
Antonella Pedrini, Elisa Rossi, Silvia Calabria, Letizia Dondi, Nello Martini
216-220
PDF
Short Communication
Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema
Fahd Quhill, Annette Beiderbeck
155-164
PDF
Sign up
Browse
Categories
Health Technology Assessment
Health Policies
banners150
Completed peer reviews since:
November 4, 2020